Immunological heterogeneity in type I diabetes: Presence of distinct autoantibody patterns in patients with acute onset and slowly progressive disease

Diabetologia

Volumn 41, Issue 8, 1998, Pages 891-897

  Seissler, J ^a   De Sonnaville, J J J ^b   Morgenthaler, N G ^a   Steinbrenner, H ^a   Glawe, D ^a   Khoo Morgenthaler, U Y ^a   Lan, M S ^c   Notkins, A L ^c   Heine, R J ^b   Scherbaum, W A ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Autoantibodies; Glutamic acid decarboxylase; Islet cell antibodies; Protein tyrosine phosphatase; Slowly progressive Type I diabetes; Type I diabetes

Indexed keywords

ADULT; AGED; ANTIBODY DETECTION; ANTIBODY PRODUCTION; AUTOIMMUNITY; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED STUDY; DISEASE CLASSIFICATION; HUMAN; HUMORAL IMMUNITY; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; PATHOGENESIS; PRIORITY JOURNAL;

ACUTE DISEASE; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AUTOANTIBODIES; CHILD; CHILD, PRESCHOOL; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; FEMALE; GLUTAMATE DECARBOXYLASE; HUMANS; INFANT; ISLETS OF LANGERHANS; MALE; MIDDLE AGED; PROTEIN-TYROSINE-PHOSPHATASE;

EID: 15644377395     PISSN: 0012186X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001250051004     Document Type: Conference Paper

References (33)

1. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus (1997) Report on the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 20: 1183-1197
2. Irvine WJ, Sawers SA, Feek CM, Prescott RJ, Duncan LJP (1979) The value of islet cell antibody in predicting secondary failure of oral hypoglycaemic agent therapy in diabetes mellitus. J Clin Lab Immunol 2: 23-26
3. Groop LC, Bottazzo GF, Doniach D (1986) Islet cell antibodies identify latent Type I diabetes in patients aged 35-75 years at diagnosis. Diabetes 35: 237-241
4. Gottsäter A, Landin-Olsson M, Fernlund P, Lernmark A, Sundkvist G (1993) β-cell function in relation to islet cell antibodies during the first 3 years after clinical diagnosis of diabetes in Type II diabetic patients. Diabetes Care 16: 902-910
5. Niskanen LK, Tuomi T, Karjalainen J Groop LC, Uusitupa MI (1995) GAD antibodies in Type I diabetes. Diabetes Care 12: 1557-1565
6. Rowley MJ, Mackay IR, Chen QY, Knowles WJ, Zimmet PZ (1992) Antibodies to glutamic acid decarboxylase discriminate major types of diabetes mellitus. Diabetes 41: 548-551
7. Kobayashi T, Nakanishi K, Okubo M, Murase T, Kosaka K (1996) GAD antibodies seldom disappear in slowly progressive IDDM. Diabetes Care 19: 1031
8. Turner R, Stratton I, Horton V et al. (1997) UKPDS 25: autoantibodies to islet-cell cytoplasm and glutamic acid decarboxylase for prediction of insulin requirement in Type II diabetes. Lancet 350: 1288-1293
9. Groop L, Miettinen A, Groop PH, Meri S, Koskimies S, Bottazzo GF (1988) Organ-specific autoimmunity and HLA-DR antigen as markers for β-cell destruction in patients with Type II diabetes. Diabetes 37: 99-103
10. Zimmet PZ, Tuomi T, Mackay IR et al. (1994) Latent autoimmune diabetes mellitus in adults (LADA): the role of antibodies to glutamic acid decarboxylase in diagnosis and prediction of insulin dependency. Diabet Med 11: 299-303
11. Tuomi T, Groop LC, Zimmet PZ, Rowley J, Knowles W, Mackay IR (1993) Antibodies to glutamic acid decarboxylase reveal latent autoimmune diabetes mellitus in adults with a non-insulin-dependent onset of disease. Diabetes 42: 359-362
12. Payton MA, Hawkes CJ, Christie MR (1995) Relationship of the 37,000- and 40,000Mr tryptic fragments of islet antigens in insulin-dependent diabetes to the protein tyrosine phosphatase-like molecule IA-2 (ICA512). J Clin Invest 96: 1506-1511
13. Lan MS, Wasserfall C, Maclaren NK, Notkins AL (1992) IA-2, a transmembrane protein of the tyrosine phosphatase family, is a major autoantigen in insulin-dependent diabetes mellitus. Proc Natl Acad Sci USA 93: 6367-6370
14. Morgenthaler N, Seissler J, Achenbach P et al. (1997) Antibodies to the tyrosine phosphatase-like protein IA-2 are highly associated with Type I diabetes, but not with autoimmune endocrine disease or Stiff Man syndrom. Autoimmunity 25: 202-212
15. Wiest-Ladenburger U, Hartmann R, Hartmann U, Berling K, Boehm BO, Richter W (1997) Combined analysis and single-step detection of GAD65 and IA-2 autoantibodies in Type I diabetes can replace the histochemical islet cell antibody test. Diabetes 46: 565-571
16. Verge CF, Gianani R, Kawasaki E et al. (1996) Prediction of Type I diabetes in first degree relatives using a combination of Insulin, GAD, and ICA512bdc/IA-2 autoantibodies. Diabetes 45: 926-933
17. Seissler J, Morgenthaler NG, Achenbach P et al. (1996) Combined screening for antibodies to IA-2 and antibodies to glutamic acid decarboxylase in first degree relatives of patients with Type I diabetes. Diabetologia 39: 1351-1356
18. Kasuga A, Ozawa Y, Maruyama T, Ishihara T, Amemiya S, Saruta T (1997) Autoantibodies against ICA512 did not improve test sensitivity for slowly progressive IDDM. Diabetes Care 20: 679-680
19. Sonnaville JJJ de, Bouma M, Colly LP, Deville W, Wijkel D, Heine RJ (1997) Sustained good glycaemic control in NIDDM patients by implementation of structured care in general practice: 2-year follow-up study. Diabetologia 40: 1334-1340
20. World Health Organisation Study Group on Diabetes mellitus (1985) Technical report series No. 727, WHO, Geneva
21. Lu J, Li Q, Xie H et al. (1996) Identification of a second transmembrane protein tyrosine phosphatase, IA-2β, as an autoantigen in insulin-dependent diabetes mellitus: precursor of the 37-kDa tryptic fragment. Proc Natl Acaol Sci USA 93: 2307-2311
22. Karlsen AE, Hagopian WA, Grubin CE et al. (1991) Cloning and primary structure of a human islet isoform of glutamic acid decarboxylase from chromosome 10. Proc Natl Acad Sci USA 88: 8337-8341
23. Scherbaum WA, Mirakian R, Pujol-Borrell R, Dean BM, Bottazzo GF (1986) Immunochemistry in the study and diagnosis of organ-specific autoimmune disease. In: Polak JM, Van Noorden S (eds) Immunochemistry. Modern methods and applications. Wright, Bistrol, pp 456-476
24. Seissler J, Hering B, Richter W et al. (1993) Antibodies to the Mr 64,000 (64 K) protein in islet cell antibody positive non-diabetic individuals indicate high risk for impaired beta-cell function. Diabetologia 35: 550-554
25. Bingley PJ, Christie MR, Bonifacio E et al. (1994) Combined analysis of autoantibodies improves prediction of Type I diabetes in islet cell antibody-positive relatives. Diabetes 43: 1304-1310
26. Christie M, Genovese S, Cassidy D et al. (1994) Antibodies to islet 37k antigen, but not to glutamate decarboxylase, discriminate rapid progression to Type I diabetes in endocrine autoimmunity. Diabetes 43: 1254-1259
27. Kawasaki E, Eisenbarth GS, Wasmeier C, Hutton JC (1996) Autoantibodies to protein tyrosine phosphatase-like proteins in Type I diabetes. Overlapping specificities to phogrin and ICA512/IA-2. Diabetes 45: 1344-1349
28. Hawkes CJ, Wasmeier C, Christie MR, Hutton JC (1996) Identification of the 37k-antigen in insulin-dependent diabetes as a tyrosine phosphatase like protein (phogrin) related to IA-2. Diabetes 45: 1187-1192
29. Ruige JB, Batstra MR, Aanstoot HJ et al. (1997) Low prevalence of antibodies to GAD65 in a 50-to 74-year-old general Dutch population. Diabetes Care 20: 1108-1110
30. Green A, Gale EAM, Patterson CC, Eurodiab Ace Study Group (1992) Incidence of childhood-onset insulin-dependent diabetes mellitus. Lancet 339: 905-907
31. Richter W, Seissler J, Northemann W, Wolfahrt S, Meinck HM, Scherbaum WA (1993) Cytoplasmic islet cell antibodies recognize distinct islet antigens in Type I diabetes but not in Stiff Man Syndrome. Diabetes 42: 1642-1648
32. Myers MA, Rabin DU, Rowley MJ. (1995) Pancreatic islet cell cytoplasmic antibody in diabetes is represented by antibodies to islet cell antigen 512 and glutamic acid decarboxylase. Diabetes 44: 1290-1295
33. Lohmann T, Seissler J, Verlohren HJ et al. (1997) Distinct genetic and immunological features in patients with insulin-dependent diabetes below and above age 40 at onset. Diabetes Care 20: 524-529